Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CID-103
Therapeutic Area : Immunology
Study Phase : Phase I
Recipient : CASI Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
CASI Pharmaceuticals Plans IND Submission for CID-103 and Receives Acquisition Proposal
Details : CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody, being investigated for the treatment of antibody-mediated rejection ("AMR") in kidney transplant.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 26, 2024
Lead Product(s) : CID-103
Therapeutic Area : Immunology
Highest Development Status : Phase I
Recipient : CASI Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibuprofen
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dexibuprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoarthritis, Knee.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 10, 2010
Lead Product(s) : Ibuprofen
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
